Study Finds Limited Impact Of New FDA Rule On 30-Month Stays In Drug Patent Challenges

Law360, New York (February 26, 2004, 12:00 AM EST) -- Last year’s decision by the U.S. Food and Drug Administration to limit 30-month stays in pharmaceutical patent challenges isn’t likely to ease the pathway to the market for generic makers, according to a new study.

Only a small fraction of abbreviated new drug applications (ANDAs) with a paragraph IV certification have faced more than one 30-month stay anyway, the survey, by business intelligence firm Cutting Edge Information, concluded.

Generics drug applicants must include with ANDAs a statement addressing the generic drug's relationship to each Orange Book-listed...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.